8 completed, 3 terminated, 1 active not recruiting, 1 withdrawn. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Terminated 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
Follow ricolinostat: new trials by email Literature Review of ricolinostat trials Research Report on ricolinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Pharmacokinetics of Ricolinostat ricolinostat - Peripheral Nervous System Diseases | Phase 1 | Completed | Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. | 12 | 2022-01-12 | 2023-04-03 |
| A Study to Investigate the Safety and Efficacy of Ricolinostat Ricolinostat - Peripheral Nervous System Diseases | Phase 1 | Completed | Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. | 10 | 2022-01-01 | 2023-12-04 |
| Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy ricolinostat, Placebo - Painful Diabetic Peripheral Neuropathy | Phase 2 | Completed | Regenacy Pharmaceuticals LLC | 282 | 2020-12-07 | 2023-09-21 |
| Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma | Phase 1 | Withdrawn | Mayo Clinic | 2017-05-01 | 2017-05-30 | |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer Paclitaxel, Ricolinostat, Bevacizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 6 | 2016-06-15 | 2019-11-08 |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL ACY-1215, Ibrutinib, Idelalisib - Recurrent Chronic Lymphoid Leukemia | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 3 | 2016-05-01 | 2026-05-19 |
| ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer ACY-1215, Nab-paclitaxel - Metastatic Breast Cancer, Breast Carcinoma | Phase 1 | Completed | Columbia University | 17 | 2016-03-01 | 2021-01-07 |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma ACY-1215 in combination with pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 | Completed | Celgene | 16 | 2014-09-15 | 2019-11-21 |
| ACY-1215 for Relapsed/Refractory Lymphoid Malignancies ACY-1215 - Lymphoma, Lymphoid Malignancies | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 23 | 2014-04-02 | 2024-08-06 |
| Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects ACY-1215 - Healthy | Phase 1 | Completed | Acetylon Pharmaceuticals Incorporated | 19 | 2014-03-01 | 2014-09-11 |
| ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Celgene | 103 | 2014-03-01 | 2025-03-04 |
| Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma ACY-1215, lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Celgene | 38 | 2012-07-12 | 2022-02-23 |
| Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma ACY-1215 - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Celgene | 120 | 2011-07-01 | 2017-04-06 |
Multiple Myeloma (4) · Peripheral Nervous System Diseases (2) · Recurrence (2) · Bile Duct Neoplasms (1) · Blood Protein Disorders (1) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Disease (1) · Disease Progression (1) · Fallopian Tube Neoplasms (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Klatskin Tumor (1) · Leukemia (1) · Leukemia, B-Cell (1)
Celgene (4) · Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. (2) · Dana-Farber Cancer Institute (2) · Acetylon Pharmaceuticals Incorporated (1) · Columbia University (1) · Jennifer Amengual (1) · Mayo Clinic (1) · Regenacy Pharmaceuticals LLC (1)
United States (11) · China (2)
Binhe Xue (1) · Jennifer B Brown, MD, PhD (1) · Jennifer E Amengual, MD (1) · Joyce Liu, MD MPH (1) · Kabir Mody (1) · Kevin Kalinsky, MD, MS (1) · Nicholas Siebers, M.D. (1) · Sagar Lonial, MD (1) · Sumit Madan, MD (1) · Xiaojiao Li (1)
P30CA015083 (1), U01CA168426 (1)